Exhibit 10.1


 


 


WARRANT EXERCISE AGREEMENT


 


This Warrant Exercise Agreement
(this “Agreement”), dated as of March 9, 2021, is by and between OpGen, Inc., a Delaware corporation (the “Company”),
and the undersigned holders (the “Holder”) of warrants to purchase shares of the Company’s common stock,
par value $0.01 per share (the “Common Stock”).


 


WHEREAS, the Holder beneficially
owns in the aggregate the number of warrants to purchase Common Stock at a current exercise price of $1.94 per share that are exercisable
until May 25, 2026, as set forth on the Holder’s signature page hereto (the “Existing Warrants”).


 


WHEREAS, the Holder desires
to exercise such Existing Warrants in the amounts set forth on the applicable signature pages hereto and, in consideration of the
Holder’s exercise of such Existing Warrants, the Company has agreed to issue the Holder, in addition to the shares of Common
Stock to which such exercising Holder is entitled pursuant to the exercise of the Existing Warrants, new warrants in the form attached
hereto as Exhibit A (the “New Warrants”) to purchase 0.65 shares of Common Stock for each share
of Common Stock issued upon such exercise of such Existing Warrants pursuant to this Agreement. The shares of Common Stock underlying
the Existing Warrants are referred to herein as the “Warrant Shares”. The shares of Common Stock underlying
the New Warrants are referred to herein as the “New Warrant Shares”.


 


NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Holder and the Company agree as follows:


 


ARTICLE I


DEFINITIONS


 


Section 1.1 Definitions.
Capitalized terms not defined in this Agreement shall have the meanings ascribed to such terms in the New Warrants.


 


ARTICLE II


EXERCISE OF EXISTING WARRANTS


 


Section 2.1 Exercise
of Warrants. (a) Subject to the conditions in Section 2(e) of the Existing Warrants, by executing this Agreement, the Company
and the Holder hereby agree that the Holder shall be deemed to have exercised the number of Existing Warrants set forth on the
signature page hereto at, in accordance with Section 2(d) of the Existing Warrants, an exercise price per share of $1.94 (the “Exercise
Price”), for aggregate cash proceeds to the Company in the amount set forth on the Holder’s signature page hereto,
pursuant to the terms of the Existing Warrants. The Holder shall deliver the aggregate cash exercise price for such Existing Warrants
to the bank account set forth on the Company’s signature page hereto within two Trading Days after the date hereof and the
Company shall deliver the Warrant Shares to the Holder via the Depository Trust Company Deposit or Withdrawal at Custodian system
pursuant to the terms of the Existing Warrants, but pursuant to DWAC instructions set forth on the Holder’s signature page
hereto. The date of the closing of the exercise of the Existing Warrants shall be referred to as the “Closing Date”.
Notwithstanding anything to the contrary contained herein, if the Holder has exercised all of its Existing Warrants on the Closing
Date, the provisions of clauses (b) and (c) of this Section 2.1, and the last sentence of Section 2.2, shall not apply to the Holder.


 


(b) After the Closing Date,
if and whenever the Holder, together with its Attribution Parties (as defined in Section 2(e) of the Existing Warrants), can exercise
the Existing Warrants for 500,000 Warrant Shares (the “Threshold Amount”) or more in compliance with the Beneficial
Ownership Limitation set forth in the Existing Warrants unless the remaining Warrant Shares are less than 500,000 and then the
exercise can be for such remaining number of Warrant Shares, the Holder hereby covenants and agrees to promptly exercise for cash
such Threshold Amount of the Existing Warrants by delivery of a Notice of Exercise pursuant to the terms and conditions of the
applicable Existing Warrants, at the Exercise Price. The parties hereto further agree that the Holder may voluntarily exercise
for cash, from time to time, the Existing Warrants pursuant to the terms and conditions of the applicable Existing Warrants at
the Exercise Price, which exercises shall count toward the number of Existing Warrants that are required to be exercised to satisfy
the Threshold Amount. As used herein “Attribution Party Pro Rata Percentage” means the percentage calculated by dividing
(i) the total number of Existing Warrants held by the Holder, by (ii) the total number of Existing Warrants held by the Holder
and its Attribution Parties.


 






    	1  





    	 



    

 


 


(c) Until the date that
no Existing Warrants are held by the Holder (the “Termination Date”), the Holder covenants and agrees (i), not
to purchase (including through the exercise of any other warrants to purchase Common Stock held by the Holder) any shares of Common
Stock of the Company, other than pursuant to exercises of Existing Warrants and (ii) not to transfer any Existing Warrants other
than to transferees who assume the obligations under this Agreement.


 


(d) Except as expressly
set forth herein, all other terms, provisions and conditions of the Existing Warrants shall continue in full force and effect without
modification.


 


Section 2.2 Issuance
of New Warrants. Within three (3) Trading Days of the Closing Date, the Company shall deliver to the Holder New Warrants to
purchase 0.65 shares of Common Stock for each share of Common Stock that the Holder receives upon the exercise for cash provided
in Section 2.1(a) above, having an initial exercise price per share equal to $3.56 (the “New Warrant Exercise Price”).
Within three (3) Trading Days of any other exercise of Existing Warrants for cash, the Company shall deliver to the Holder New
Warrants to purchase 0.65 shares of Common Stock for each share of Common Stock that the Holder receives upon such exercise for
cash, having an initial exercise price per share equal to the New Warrant Exercise Price. In addition, within three (3) Trading
Days of the Closing Date or any other exercise of Existing Warrants, as the case may be, the Holder shall pay to the Company (to
the bank account set forth on Exhibit B hereto) a cash payment of $0.10 for each New Warrant issued to the Holder.


 


Section 2.3 Legends;
Restricted Securities. (a) The Holder understands that the New Warrants and the shares of Common Stock underlying New
Warrants are not, and may never be, registered under the Securities Act of 1933, as amended (the “Securities Act”),
or the securities laws of any state and, accordingly, each certificate, if any, representing such securities shall bear a legend
substantially similar to the following:


 


“THIS SECURITY HAS NOT BEEN
REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE
OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER
OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES
ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.”


 






    	2  





    	 



    

 


 


(b) Certificates evidencing
shares of Common Stock underlying the New Warrants shall not contain any legend (including the legend set forth in Section 2.3(a)
hereof), (i) while a registration statement covering the resale of such Common Stock is effective under the Securities Act, (ii)
following any sale of such Common Stock pursuant to Rule 144, (iii) if such Common Stock is eligible for sale under Rule 144, without
the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Common
Stock and without volume or manner-of-sale restrictions, (iv) if such Common Stock may be sold under Rule 144 and the Company is
then in compliance with the current public information required under Rule 144 as to such Common Stock, or (v) if such legend is
not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued
by the staff of the Securities and Exchange Commission (the “Commission”)). The Company shall cause its counsel
to issue a legal opinion to the transfer agent promptly after the Delegend Date (as defined below) if required by the Company and/or
the transfer agent, or if requested by the Holder, in connection with the removal of the legend hereunder, which opinion shall
be in form and substance reasonably acceptable to the Holder. If such Common Stock may be sold under Rule 144 without the requirement
for the Company to be in compliance with the current public information required under Rule 144, if such Common Stock may be sold
under Rule 144 and the Company is then in compliance with the current public information required under Rule 144 as to such Common
Stock, or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations
and pronouncements issued by the staff of the Commission) then such Common Stock shall be issued free of all legends. The Company
agrees that following the Delegend Date or at such time as such legend is no longer required under this Section 2.3(b), it will,
no later than two (2) Trading Days following the delivery by the Holder to the Company or the transfer agent of a certificate representing
the Common Stock underlying the New Warrants issued with a restrictive legend (such second Trading Day, the “Legend Removal
Date”), deliver or cause to be delivered to the Holder a certificate representing such shares that is free from all restrictive
and other legends or, at the request of the Holder shall credit the account of the Holder’s prime broker with the Depository
Trust Company System as directed by the Holder. The Company may not make any notation on its records or give instructions to the
transfer agent that enlarge the restrictions on transfer set forth in this Section 2.3(b). “Delegend Date” means
the earliest of the date that (a) a registration statement with respect to the Common Stock has been declared effective by the
Commission, (b) all of the Common Stock has been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement
for the Company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale
restrictions or (c) following the six (6) month anniversary of (I) the issuance date of the applicable New Warrant if a New Warrant
is exercised pursuant to a cashless exercise or (II) the date of the related cash exercise of the New Warrants provided, in each
case that the applicable holder of the New Warrants or the Common Stock, as the case may be, is not an Affiliate of the Company,
the Company is in compliance with the current public information required under Rule 144 (“Current Public Information
Requirement”) and all such Common Stock may be sold pursuant to Rule 144 or an exemption from registration under Section
4(a)(1) of the Securities Act without volume or manner-of-sale restrictions; provided, further, however, that if the Company fails
to comply with the Current Public Information Requirement at any time following the applicable six (6) month anniversary set forth
above and prior to the date that is six (6) months thereafter, the Company shall promptly provide notice to the Holder and the
Holder undertakes not to sell such Common Stock pursuant to Rule 144 until the Company notifies the Holder that it has regained
compliance with the Current Public Information Requirement; and provided further, that if a delegending is in effect
solely as the result of the effectiveness of a registration statement covering the resale of any Common Stock, the Holder undertakes
not to sell any such Common Stock if the Holder is notified or otherwise becomes aware that such registration statement has been
withdrawn or suspended, contains a material misstatement or omission or has become stale. The Holder agrees with the Company that
the Holder will sell or transfer any New Warrants or shares of Common Stock underlying New Warrants pursuant to either the registration
requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that
if such securities are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution
set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing any such securities
as set forth in this Section 2.3 or otherwise is predicated upon the Company’s reliance upon this understanding.


 






    	3  





    	 



    

 


  


Section 2.4 Registration.
During any time in which the Company is unable to keep the Registration Statement effective and available despite its commercially
reasonable efforts, notwithstanding anything to the contrary contained in this Agreement, the Holder shall not be required to exercise
any remaining Existing Warrants under this Agreement and the Holder shall not be restricted by the provisions of clause (i) of
Section 2.1(c) above. As soon as practicable (and in any event within 45 calendar days of the full exercise by the Holder of all
the outstanding Existing Warrants (the “Final Exercise Date”)), the Company shall file a registration statement
on Form S-3 or Form S-1 (the “New Registration Statement”) providing for the resale by the Holder of the New
Warrant Shares issued and issuable upon exercise of the New Warrants.  The Company shall use commercially reasonable efforts
to cause such registration to become effective within 90 days following the Final Exercise Date and to keep such registration statement
effective at all times until the Holder no longer owns the New Warrants or any New Warrant Shares issuable upon exercise thereof.
Notwithstanding the foregoing, in the event Final Exercise Date occurs at such a time when the filing of the New Registration Statement
cannot be filed under SEC rules and regulations until such time as the Company files its 10-K (as defined below) or the SEC informs
the Company that it will review the New Registration Statement, the time periods set forth herein shall be tolled until such time
as the Company files its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “10-K”).


 


Section 2.5  Filing
of Form 8-K. Prior to 9:00 am ET on March 10, 2021, the Company shall issue a Current Report on Form 8-K, reasonably acceptable
to the Holder disclosing the material terms of the transactions contemplated hereby, which shall include this form of Agreement
(the “8-K Filing”). From and after the issuance of the 8-K Filing, the Company represents to the Holder that
it shall not be in possession of any material, nonpublic information received from the Company, any of its Subsidiaries or any
of their respective officers, directors, employees or agents, that is not disclosed in the 8-K Filing. In addition, effective upon
the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under
any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
employees or agents, on the one hand, and the Holder or any of its affiliates, on the other hand, shall terminate. The Company
shall not, and shall cause each of its Subsidiaries and its and each of their respective officers, directors, employees and agents,
not to, provide the Holder with any material, nonpublic information regarding the Company or any of its Subsidiaries from and after
the date hereof without the express prior written consent of the Holder. To the extent that the Company, any of its Subsidiaries
or any of their respective officers, directors, employees or agents, delivers any material, non-public information to the Holder
without the Holder’s consent, the Company hereby covenants and agrees that the Holder shall not have any duty of confidentiality
with respect to, or a duty not to trade on the basis of, such material, non-public information.


  


ARTICLE III


REPRESENTATIONS AND WARRANTIES


 


Section 3.1 Representations
and Warranties of the Company. The Company hereby makes the representations and warranties set forth below to the Holder that
as of the date of its execution of this Agreement and agrees to the covenants set forth below:


 


(a) Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery
of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by
all necessary action on the part of such Company and no further action is required by such Company, its board of directors or its
stockholders in connection therewith. This Agreement has been duly executed by the Company and, when delivered in accordance with
the terms hereof will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.


 






    	4  





    	 



    

 


 


(b) Organization.
The Company is a duly organized and validly existing corporation in good standing under the laws of the State of Delaware.


 


(c) Registration
Statement. The Warrant Shares are registered for issuance on a Registration Statement on Form S-3 (File No. 333-250983) (the
“Registration Statement”) and the Company knows of no reasons why such registration statement shall not remain
available for the issuance of such Warrant Shares for the foreseeable future. The Company shall use commercially reasonable efforts
to keep the Registration Statement effective and available for the issuance of the Warrant Shares underlying the Existing Warrants
until all Existing Warrants are exercised. During any time in which the Company is unable to keep the Registration Statement effective
and available despite its commercially reasonable efforts, notwithstanding anything to the contrary contained in this Agreement,
the Holder shall not be required to exercise any remaining Existing Warrants under this Agreement and the Holder shall not be restricted
by the provisions of clause (i) of Section 2.1(c) above.


 


(d) No Conflicts.
The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions
contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any lien upon any of the properties
or assets of the Company, or give to others any rights of termination, amendment, acceleration or cancellation (with or without
notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company
debt or otherwise) or other material understanding to which the Company is a party or by which any property or asset of the Company
is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction,
decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state
securities laws and regulations), or by which any property or asset of the Company is bound or affected.


 


(e) Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by this Agreement and any other information
that will be public after the issuance of the 8-K Filing, the Company confirms that neither it nor any other Person acting on its
behalf has provided any of Holder or their agents or counsel with any information that it believes constitutes or might constitute
material, non-public information. The Company understands and confirms that the Holder will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Holder
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including but
not limited to the disclosure set forth in the SEC Reports, is true and correct in all material respects and does not contain any
untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein,
in light of the circumstances under which they were made, not misleading. As used herein, “SEC Reports” means
all reports, schedules, forms, statements and other documents required to be filed by the Company with the Commission pursuant
to the reporting requirements of the Securities Exchange Act of 1934, as amended, including all exhibits included therein and financial
statements, notes and schedules thereto and documents incorporated by reference therein.


 


(f) Issuance of
Securities. The issuance of the New Warrants are duly authorized and, upon issuance in accordance with the terms of this Agreement,
the New Warrants shall be validly issued and free from all preemptive or similar rights (except for those which have been validly
waived prior to the date hereof), taxes, liens and charges and other encumbrances with respect to the issue thereof. As of the
Closing Date, a number of shares of Common Stock shall have been duly authorized and reserved for issuance which equals or exceeds
the maximum number of New Warrant Shares issuable upon exercise of the New Warrants (without taking into account any limitations
on the exercise of the New Warrants set forth therein). Upon exercise of the New Warrants in accordance with the New Warrants,
the New Warrant Shares when issued will be validly issued, fully paid and nonassessable and free from all preemptive or similar
rights, taxes, liens, charges and other encumbrances with respect to the issue thereof, with the holders being entitled to all
rights accorded to a holder of Common Stock. Assuming the accuracy of each of the representations and warranties set forth in Section
3.2 of this Agreement, the offer and issuance by the Company of the New Warrants is exempt from registration under the Securities
Act.


 






    	5  





    	 



    

 


 


(g) No General
Solicitation. Neither the Company, nor any of its Subsidiaries or affiliates, nor any Person acting on its or their behalf,
has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with
the offer or sale of the New Warrants.


 


(h) No Integrated
Offering. None of the Company, its Subsidiaries or any of their affiliates, nor any Person acting on their behalf has, directly
or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would
require registration of the issuance of any of the New Warrants or the shares of Common Stock underlying the New Warrants (collectively,
the “Securities”) under the Securities Act, whether through integration with prior offerings or otherwise, or
cause this offering of the Securities to require approval of shareholders of the Company for purposes of the Securities Act or
any applicable shareholder approval provisions, including, without limitation, under the rules and regulations of any exchange
or automated quotation system on which any of the securities of the Company are listed or designated for quotation. None of the
Company, its Subsidiaries, their affiliates nor any Person acting on their behalf will take any action or steps that would require
registration of the issuance of any of the Securities under the Securities Act or cause the offering of any of the Securities to
be integrated with other offerings for purposes of any such applicable shareholder approval provisions.


 


(i) No Disqualification
Events. With respect to Securities to be offered and sold hereunder in reliance on Rule 506(b) under the Securities Act (“Regulation
D Securities”), none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer,
other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company’s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule
405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered
Person” and, together, “Issuer Covered Persons”) is subject to any of the “Bad Actor”
disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification Event”),
except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine
whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with
its disclosure obligations under Rule 506(e), and has furnished to the Holder a copy of any disclosures provided thereunder.


 


(j) Issued and
Outstanding Shares. As of the date hereof, the Company has issued and outstanding 38,591,876 shares of Common Stock.


  


Section 3.2 Representations
and Warranties of the Holder. The Holder hereby makes the representations and warranties set forth below to the Company
that as of the date of its execution of this Agreement.


 


(a) Due Authorization.
The Holder represents and warrants that (i) the execution and delivery of this Agreement by it and the consummation by it of the
transactions contemplated hereby have been duly authorized by all necessary action on its behalf and (ii) this Agreement has been
duly executed and delivered by the Holder and constitutes the valid and binding obligation of the Holder, enforceable against it
in accordance with its terms.


 


(b) No Conflicts.
The Holder represents and warrants that the execution, delivery and performance of this Agreement by the Holder and the consummation
by the Holder of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Holder’s
organizational or charter documents, or (ii) conflict with or result in a violation of any agreement, law, rule, regulation, order,
judgment, injunction, decree or other restriction of any court or governmental authority which would interfere with the ability
of the Holder to perform its obligations under this Agreement.


 


(c) Access to Information.
The Holder acknowledges that it has had the opportunity to review this Agreement and the SEC Reports and has been afforded (i)
the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company
concerning the terms and conditions of the exercise of the Existing Warrants and the merits and risks of investing in the Securities;
(ii) access to information about the Company and its financial condition, results of operations, business, properties, management
and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information
that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment
decision with respect to the investment. The Holder acknowledges and agrees that neither A.G.P./Alliance Global Partners (the “Advisor”)
nor any Affiliate of the Advisor has provided the Holder with any information or advice with respect to the Securities nor is such
information or advice necessary or desired. Neither the Advisor nor any Affiliate has made or makes any representation as to the
Company or the quality of the securities issued and issuable hereunder and the Advisor and any Affiliate may have acquired non-public
information with respect to the Company which the Holder agrees need not be provided to it. In connection with the issuance of
the securities hereunder to the Holder, neither the Advisor nor any of its Affiliates has acted as a financial advisor or fiduciary
to the Holder.


 






    	6  





    	 



    

 


 


(d) Holder Status.
The Holder represents and warrants that is an “accredited investor” as defined in Rule 501 under the Securities Act.


 


(e) Knowledge.
The Holder, either alone or together with its representatives, has such knowledge, sophistication and experience in business and
financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has
so evaluated the merits and risks of such investment. The Holder is able to bear the economic risk of an investment in the Securities
and, at the present time, is able to afford a complete loss of such investment.


 


ARTICLE IV


MISCELLANEOUS


 


Section 4.1 Subsequent
Equity Sales.


 


(a) From the date hereof
until the earlier of 60 days after the Closing Date (the “Trigger Date”), neither the Company nor any Subsidiaries
thereof shall, directly or indirectly, file any registration statement or any amendment or supplement thereto, or cause any registration
statement to be declared effective by the Commission, or grant any registration rights to any Person that can be exercised prior
to such time as set forth above, other than pursuant to the terms of Section 2.4 hereof; provided, however, that the Company shall
be permitted to file a shelf-registration statement on Form S-3 45 days after the Closing Date. From the date hereof until the
Trigger Date, the Company shall not, (1) directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose
of (or announce any offer, sale, grant or any option to purchase or other disposition of) any of its or its Subsidiaries’
debt, equity or equity equivalent securities, including without limitation any debt, preferred stock or other instrument or security
that is, at any time during its life and under any circumstances, convertible into or exchangeable or exercisable for the Company’s
Common Stock or Common Stock Equivalents (as defined below), including, without limitation, any rights, warrants or options to
subscribe for or purchase the Company’s Common Stock or directly or indirectly convertible into or exchangeable or exercisable
for the Company’s Common Stock at a price which varies or may vary with the market price of the Company’s Common Stock
, including by way of one or more reset(s) to any fixed price (any such offer, sale, grant, disposition or announcement being referred
to as a “Subsequent Placement”), (2) enter into, or effect a transaction under, any agreement, including, but
not limited to, an equity line of credit or “at-the-market” offering, whereby the Company may issue securities at a
future determined price or (3) be party to any solicitations, negotiations or discussions with regard to the foregoing. As used
herein “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle
the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option,
warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the
holder thereof to receive, Common Stock.


 


(b) Notwithstanding the
foregoing, this Section 4.1 shall not apply in respect of an Exempt Issuance. “Exempt Issuance” means the issuance
of (a) shares of Common Stock or options to employees, officers, directors or consultants of the Company pursuant to any share
or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors of the Company
or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the
Company, (b) securities upon the exercise or exchange of or conversion of securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended
since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or
conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such
securities and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested
directors of the Company, provided that such securities are issued as “restricted securities” (as defined in Rule 144)
and carry no registration rights that require or permit the filing of any registration statement in connection therewith during
the prohibition period in Section 4.1(a) and provided that any such issuance shall only be to a Person (or to the equityholders
of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic
with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but
shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an
entity whose primary business is investing in securities.


 






    	7  





    	 



    

 


 


(c) The Holder hereunder
was the purchaser under that certain Securities Purchase Agreement, dated February 9, 2021, by and between the Company and the
purchaser parties thereto, and hereby waives the application of and restrictions set forth in Section 4.12 of such Securities Purchase
Agreement with respect to the transactions contemplated by this Agreement and the ATM Agreement.


 


Section 4.2 Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be made by email
to the email address of the Holder set forth on Holders’ signature page.


 


Section 4.3 Survival.
All warranties and representations (as of the date such warranties and representations were made) made herein or in any certificate
or other instrument delivered by it or on its behalf under this Agreement shall be considered to have been relied upon by the parties
hereto and shall survive the issuance of the New Warrants. This Agreement shall inure to the benefit of and be binding upon the
successors and permitted assigns of each of the parties; provided however that no party may assign this Agreement or the obligations
and rights of such party hereunder without the prior written consent of the other parties hereto.


  


Section 4.4 Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.


 


Section 4.5 Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Agreement.


 


Section 4.6 Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined
pursuant to Section 5(e) of the New Warrants.


 


Section 4.7 Entire
Agreement. The Agreement, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.


 


Section 4.8 Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.


 


 Section 4.9 Fees
and Expenses. Except as expressly set forth herein, each party shall pay the fees and expenses of its advisers, counsel, accountants
and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery
and performance of this Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied
in connection with the delivery of any Warrant Shares or New Warrant Shares.


 


(remainder of page intentionally left blank;
signature page follows)


 


 




    	8  





    	 



    

 


IN WITNESS WHEREOF,
the undersigned have executed this Warrant Exercise Agreement as of the date first written above.


 


	COMPANY:	 
	 	 
	OPGEN, INC.	 
	 	 
	 	 
	By:	 /s/ Timothy C. Dec	 
	Name:      	Timothy C. Dec	 
	Title:	 Chief Financial Officer	 


 


 


 


 


 




    	  





    	 



    


 


[HOLDER SIGNATURE PAGES TO OPGEN, INC. 


WARRANT EXERCISE AGREEMENT]


 


IN WITNESS WHEREOF, the undersigned have caused
this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.


 


	Name of Holder:	 	 


 


	Signature of Authorized Signatory of Holder:	 	 


 


	Name of Authorized Signatory:	 	 


 


	Title of Authorized Signatory:	 	 


 


	Email Address of Holder:	 	 


 


	Number of Existing Warrants held:	 	 


 


	Number of Existing Warrants deemed exercised:	 	 


 


	Aggregate Exercise Price of Existing Warrants deemed exercised:	 	 


 


	Warrant Shares underlying Existing Warrants deemed exercised:	 	 


 


	Instructions for Warrant Shares to be issued upon initial exercise of

Existing Warrants:	 	 


 


	
        Number of New Warrants to be issued to Holder upon

        deemed exercise:
	 	 


 


	Address for Delivery of New Warrants for Holder:	 	 
	 	 	 


 


 




    	  





    	 



    


 


Exhibit A


 


New Warrant


 


 


 


 


 


 


 


 




    	  





    	 



    


 


Exhibit B


 


Bank Account and Wire Instructions